Sean M. Boyle, Ph.D.
Affiliations: | Genetics, Genomics and Bioinformatics | University of California, Riverside, Riverside, CA, United States |
Google:
"Sean Boyle"Mean distance: 18.05 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentorAnandasankar Ray | grad student | 2012 | UC Riverside | |
(Computational Analysis of Receptor-Odor Interactions and Prediction of Behavior-Modifying Chemical Space.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Abbott C, Bedi N, Zhang SV, et al. (2020) Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck. Journal of Clinical Oncology. 38: 6557-6557 |
Abbott CW, Bedi N, Zhang SV, et al. (2020) Abstract B18: Exome scale liquid biopsy monitoring of putative neoantigens and genomic biomarkers in patients on anti-PD-1 therapy in squamous cell carcinoma of the head and neck Cancer Immunology Research. 8 |
Pyke RM, Abbott C, Mellacheruvu D, et al. (2020) Abstract 6678: Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy Cancer Research. 80: 6678-6678 |
Abbott CW, Levy E, Pyke RM, et al. (2020) Abstract 4278: A composite neoantigen score is more strongly associated with therapeutic response than tumor mutational burden in a cohort of late-stage anti-PD-1-treated melanoma patients Clinical Trials. 80: 4278-4278 |
Zhang SV, Tan M, Northcott JM, et al. (2020) Abstract 1989: Enhanced whole exome profiling of tumor circulating cell-free DNA enables sensitive assessment of tumor mutations Clinical Trials. 80: 1989-1989 |
Power RP, Bartha G, Harris J, et al. (2020) Abstract 1334: A diagnostic platform for precision cancer therapy enabling composite biomarkers by combining tumor and immune features from an enhanced exome and transcriptome Cancer Research. 80: 1334-1334 |
Mellacheruvu D, Phillips N, Bartha G, et al. (2019) Abstract 4536: Applying immunopeptidomics and machine learning to improve neoantigen prediction for therapeutic and diagnostic use Cancer Research. 79: 4536-4536 |
Zhang SV, Abbott C, Li R, et al. (2019) Abstract 4695: Development and validation of an accurate exome-scale cfDNA detection platform Cancer Research. 79: 4695-4695 |
Power R, Bartha G, Harris J, et al. (2019) Abstract A051: A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample Molecular Cancer Therapeutics. 18 |
Wang J, Boyle SM, Lee C, et al. (2018) Abstract 5710: Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment Cancer Research. 78: 5710-5710 |